为了解 TP53 突变 在分子层面的变化并明确移植后的分层预后结果，研究人员对 63 例接受移植的 TP53 突变 急性髓系白血病（AML）/ 骨髓增生异常综合征（MDS）患者开展研究。结果显示 AML 和 TP53 克隆优势 是预后因素，该研究有助于移植决策。

复旦大学附属华东医院血液科近日在血液领域权威期刊Blood Cancer Journal上在线发表了题为“Decitabine with etoposide is effective in TP53 mutated myeloid tumors via ...

编辑推荐：针对高危急性髓系白血病(AML)患者疗效预测难题，日本多中心团队通过70基因NGS panel分析29例接受NS-87/CPX-351治疗的 ...

复旦大学附属华东医院血液科近日在血液领域权威期刊Blood Cancer Journal上在线发表了题为“Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block”的论文。

During 2024 and into 2025, we continue to advance our lead investigational drug tuspetinib in combination with venetoclax and azacitidine for ...

Research and development expenses decreased by $21.7 million to $15.1 million for year ended December 31, 2024, as compared to $36.8 million for the comparable period in 2023. Changes to the ...

in difficult-to-treat and underserved TP53-mutated/CK AML and FLT3-wildtype AML patients in our ongoing TUSCANY trial. We look forward to sharing more data as the trial evolves.” Financing ...

At 40 mg TUS, the triplet therapy achieved complete remissions (CRs) in difficult-to-treat TP53-muated AML and FLT3-wildtype AML patients, including a measurable residual disease (MRD) negative ...